Gadolinium Retention in Brain and Body Tissues: Safety Considerations

Alberto Spinazzi, MD
Head, Global Medical and Regulatory Affairs
Bracco Group

Medical Imaging Drugs Advisory Committee (MIDAC) Meeting
Silver Spring, MD
September 8, 2017
Introduction
Bracco Position

- Bracco is a global pharmaceutical group, with Clinical, Medical and Regulatory operations headquartered in the United States
- The recent findings on long-term retention of gadolinium (Gd) complexes in tissues following exposure to gadolinium-based contrast agents (GBCAs) are taken very seriously by Bracco
- Although much is still unknown (e.g., risk factors, potential association with adverse health effects), it is prudent and appropriate to further inform health care professionals and the public about the finding of retention in the brain and other organs
Bracco Position

• Bracco fully supports FDA’s initiatives for:
  − Updating/enhancing the labeling of gadolinium-based contrast agents (GBCAs) based on their individual benefit-risk profile
  − Developing a collaborative effort to better understand this phenomenon and mitigate any potential risk of Gd retention in patients
    ➢ Including ways to reduce exposure through dose reduction without compromising efficacy (as for example has been effective in radiation exposure in CT – the “As Low As Reasonably Achievable”, ALARA principle)
Bracco Position

When looking at nephrogenic systemic fibrosis (NSF), the only serious medical condition associated with Gd retention in tissues to date, it is clear that the response of FDA has been extremely effective at significantly reducing the risk of its occurrence:

- Introduced agent-specific warnings and restrictions in patients at risk, based on clinical evidence
- Did not segregate the approved products merely on the basis of their chemical structure, or based upon results of animal experiments
- Eight years later, a large amount of new clinical evidence, in part derived from FDA-requested post-marketing safety studies, further validates the Agency’s 2009 evidence-based approach
Incidence of Nephrogenic Systemic Fibrosis in High-Risk Patients – Evidence from Clinical Studies

<table>
<thead>
<tr>
<th>GBCA</th>
<th>Incidence of NSF (N of NSF cases / N of high-risk patients a)</th>
<th>Upper Bound of 95% Confidence Interval (Clopper-Pearson Exact Method)</th>
<th>Upper Bound of 95% Confidence Interval (Wilson Score Interval Approximate Method)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MultiHance®</td>
<td>0/8486</td>
<td>0.0435%</td>
<td>0.0452%</td>
</tr>
<tr>
<td>Dotarem®</td>
<td>0/502</td>
<td>0.7321%</td>
<td>0.7594%</td>
</tr>
<tr>
<td>Gadavist®</td>
<td>0/284</td>
<td>1.2905%</td>
<td>1.3346%</td>
</tr>
<tr>
<td>ProHance®</td>
<td>0/153</td>
<td>2.3822%</td>
<td>2.4493%</td>
</tr>
<tr>
<td>Eovist®</td>
<td>0/85</td>
<td>4.2470%</td>
<td>4.3239%</td>
</tr>
<tr>
<td>Optimark®</td>
<td>Not Available</td>
<td>Not Available</td>
<td>Not Available</td>
</tr>
<tr>
<td>Magnevist®</td>
<td>12/498 (2.4%)</td>
<td>4.1713%</td>
<td>4.1642%</td>
</tr>
<tr>
<td>Omniscan™</td>
<td>79/1673 (4.7%)</td>
<td>5.8506%</td>
<td>5.8463%</td>
</tr>
</tbody>
</table>

a Patients with end-stage renal disease or eGFR <30 mL/min/1.73 m², and/or during the perioperative liver transplantation period

Source: Bracco Briefing Material, Section 3.2.2.1, Table R
Differences Among Linear GBCAs Recognized By Health Care Providers

- Marked and steady decrease in the use of the 3 linear agents affected by higher rates of NSF (Magnevist®, Omniscan™, OptiMARK®)
- But, progressive and marked increase in the use of MultiHance®, due to its more favorable benefit-risk profile

Source: FDA Briefing Material, Page 107
Problem Statement
### Benefit-Risk Balance of Use of Gadolinium-Based Contrast Agents

<table>
<thead>
<tr>
<th>Benefit</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GBCAs provide critical medical information</strong></td>
<td><strong>Known Risk</strong>&lt;sup&gt;3-4&lt;/sup&gt;</td>
</tr>
<tr>
<td>• Part of standard clinical practice to enhance the diagnostic effectiveness of magnetic resonance imaging (MRI) for over 30 years in more than 300 million patients</td>
<td>• Acute (immediate-type) adverse events</td>
</tr>
<tr>
<td>• Their use is an essential component in the diagnosis, monitoring and follow-up of a variety of clinical conditions</td>
<td>• Breath-holding difficulty with gadoxetate disodium (Eovist®)</td>
</tr>
<tr>
<td></td>
<td>• Extravasation</td>
</tr>
<tr>
<td></td>
<td>• Retention of gadolinium (Gd) in tissues and association with Nephrogenic Systemic Fibrosis (NSF)</td>
</tr>
<tr>
<td></td>
<td><strong>Potential (Unknown) Risk</strong></td>
</tr>
<tr>
<td></td>
<td>• Non-NSF adverse events reported in conjunction with Gd retention in brain and body tissues?</td>
</tr>
</tbody>
</table>

---


---

MIDAC Meeting – September 8, 2017
Gd Retention – Risk Assessment Beyond NSF

Retention of Gd Complexes in Human Patients With or Without Impairment of Renal Function

Brain Tissues
• T1 Hyperintensity in Deep Brain Areas on Unenhanced Brain MR images
• Potential Association with Adverse Health Effects?

Extracerebral (Body) Tissues
• Potential Association with Non-NSF, Adverse Health Effects?
  • Symptoms occurring usually hours/days/weeks after exposure to all approved GBCAs and lasting for ≥4 weeks
Summary of Available Evidence
Evidence of Long-Term Gd Retention: Hierarchical Framework – 1

Key findings:

- Retained Gd levels extremely small, especially in brain tissues (10 to >100 times lower than in body tissues)

- Brain tissues:
  - Not a clear demarcation between all macrocyclic GBCAs and linear GBCAs:
    - ProHance < Gadavist/MultiHance/Magnevist < Omniscan
  - (no data with Dotarem and OptiMARK)

- Body Tissues (e.g., skin, bone, liver):
  - Observed following exposure to all GBCAs, linear and macrocyclic

Highest level of evidence: Direct demonstration of presence, levels and localization of Gd complexes in HUMAN TISSUES using highly reliable, specific and sensitive methods

1. Bracco Briefing Material, Sections 2.1.1.2 and 2.2.2; 2. Murata et al. Invest Radiol 2016; 51: 447-53

MIDAC Meeting – September 8, 2017
### TABLE 3. Gd Deposition Ratio Amount per Gram Tissue per Millimole Administered

<table>
<thead>
<tr>
<th>Case ID</th>
<th>GBCA</th>
<th>No. of CEMRI</th>
<th>Total Dose, mL</th>
<th>Total Dose, mmol</th>
<th>Gd Deposition, μg/g Tissue</th>
<th>Gd Deposition Ratio, μg/g/mmol</th>
<th>Last-First CEMRI Before Death, d</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Gadobutrol (Gadovist)</td>
<td>1</td>
<td>5</td>
<td>5</td>
<td>0.625 1.070 NA</td>
<td>0.125 0.214 —</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>Gadobutrol (Gadovist)</td>
<td>2</td>
<td>20</td>
<td>20</td>
<td>0.188 0.111 5.280</td>
<td>0.009 0.006 0.264</td>
<td>392–441</td>
</tr>
<tr>
<td>3</td>
<td>Gadoteridol (ProHance)</td>
<td>1</td>
<td>24</td>
<td>12</td>
<td>0.066 0.078 0.754</td>
<td>0.006 0.007 0.063</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>Gadoteridol (ProHance)</td>
<td>11</td>
<td>126</td>
<td>63</td>
<td>0.039 NA 1.620</td>
<td>0.001 — 0.026</td>
<td>19–318</td>
</tr>
<tr>
<td>5</td>
<td>Gadoteridol (ProHance)</td>
<td>3</td>
<td>57</td>
<td>28.5</td>
<td>0.023 NA 0.428</td>
<td>0.001 — 0.015</td>
<td>53–818</td>
</tr>
<tr>
<td>6</td>
<td>Gadoteridol (ProHance)</td>
<td>1</td>
<td>18</td>
<td>9</td>
<td>0.008 &lt;0.004 0.098</td>
<td>0.001 &lt;0.001 0.011</td>
<td>118</td>
</tr>
<tr>
<td>7</td>
<td>Gadoteridol (ProHance)</td>
<td>1</td>
<td>20</td>
<td>10</td>
<td>&lt;0.005 &lt;0.005 0.094</td>
<td>&lt;0.001 &lt;0.001 0.009</td>
<td>90</td>
</tr>
<tr>
<td>8</td>
<td>Gadoxetate (Eovist)</td>
<td>10</td>
<td>100</td>
<td>25</td>
<td>0.148 NA 1.300</td>
<td>0.006 — 0.052</td>
<td>90–819</td>
</tr>
<tr>
<td>9</td>
<td>Gadobenate (MultiHance)</td>
<td>1</td>
<td>20</td>
<td>10</td>
<td>0.052 0.078 2.380</td>
<td>0.005 0.008 0.238</td>
<td>83</td>
</tr>
</tbody>
</table>

Murata et al., Invest Radiol. 2016; 51: 447-453
Evidence of Long-Term Gd Retention: Hierarchical Framework – 2

**Lower level of evidence: Direct demonstration** of presence, levels and localization of Gd complexes in ANIMAL TISSUES

**Key findings:**

- Retained Gd levels extremely small after very high cumulative doses (brain tissues << body tissues)

- **Brain tissues:**
  - ProHance < Dotarem/Gadavist < MultiHance < Magnevist << Omniscan

- **Body Tissues (e.g., skin, bone, liver, kidney):**
  - Observed following exposure to all GBCAs, with differences in Gd retention among individual GBCAs dependent on animal species, individual organs tested, and experimental models used
  - Studies with Dotarem and MultiHance in juvenile animals did not show remarkable differences in body retention between the two agents

---

1. Bracco Briefing Material, Section 2.1.1.1; 2. Bracco Briefing Material, Section 2.2.1
Evidence of Long-Term Gd Retention: Hierarchical Framework – 3

**Key findings:**

1. A systematic trend observed for ProHance (no effect on SI) and Omniscan and Magnevist (always determining significant changes in SI in the dentate nucleus, DN, and globus pallidus, GP)
2. Mixed results observed after Eovist, MultiHance, Gadavist and Dotarem (with a majority of studies not showing a significant effect in the DN and GP)
3. Visible T1 hyperintensity in deep brain areas more robustly associated with previous administration of certain linear GBCAs (Magnevist, Omniscan) compared with other GBCAs

**Lowest level of evidence (for brain retention only):** Studies aimed at detecting changes in signal intensity (SI) on unenhanced T1-weighted images or $r_1$ relaxation rate (R1) in deep brain areas

- Dependent on: a) the method used for quantitative analysis of changes in SI, and b) individual readers
- Cannot determine levels of retained Gd in brain tissues

1. Bracco Briefing Material, Section 2.1.2
## Summary of Results of Clinical Imaging Studies

(Source: Bracco Briefing Material, Section 2.1.2, Table B, Pages 39-40)

<table>
<thead>
<tr>
<th>GBCA</th>
<th>Significant effect on SI or relaxation rate</th>
<th>No significant effect on SI or relaxation rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProHance</td>
<td>a. Adult patients</td>
<td>a. Kanda et al., 2015</td>
</tr>
<tr>
<td></td>
<td>b. Pediatric patients</td>
<td>b. Tibussek et al., 2017</td>
</tr>
<tr>
<td>Magnevist</td>
<td>a. Kanda et al., 2014; Kanda et al., 2015; Adin et al., 2015; Radbruch et al., 2015a; Radbruch et al., 2015b; Tedeschi et al., 2016; Cao et al., 2016a; Tanaka et al., 2016; Radbruch et al., 2016; Cao et al., 2016b; Zhang et al., 2017; Schlemm et al., 2017; Kuno et al., 2017; Bae et al., 2017; Radbruch et al., 2017b; Forslin et al., 2017</td>
<td>b. Hu et al., 2016; Roberts et al., 2016a; Flood et al., 2017</td>
</tr>
<tr>
<td></td>
<td>b. Hu et al., 2016; Roberts et al., 2016a; Flood et al., 2017</td>
<td></td>
</tr>
<tr>
<td>Omniscan</td>
<td>a. Kanda et al., 2014; Errante et al., 2104; Quattrocchi et al., 2015; McDonald et al., 2015; Ramalho et al., 2015; Ramalho et al., 2016a; Tanaka et al., 2016; Ramalho et al., 2016b; Cao et al., 2016b; Zhang et al., 2017; Bae et al., 2017; Ichikawa et al., 2017; Radbruch et al., 2017b; Forslin et al., 2017</td>
<td>b. No data available</td>
</tr>
<tr>
<td></td>
<td>b. No data available</td>
<td></td>
</tr>
<tr>
<td>Dotarem</td>
<td>a. Tedeschi et al., 2016</td>
<td>a. Radbruch et al., 2015b; Eisele et al., 2016; Bae et al., 2017; Radbruch et al., 2017b; Eisele et al., 2017b</td>
</tr>
<tr>
<td></td>
<td>b. Rossi-Espagnet et al., 2017</td>
<td>b. Tibussek et al., 2017</td>
</tr>
<tr>
<td>Eovist</td>
<td>a. Kahn et al., 2017</td>
<td>a. Ichikawa et al., 2017; Conte et al, 2017</td>
</tr>
<tr>
<td></td>
<td>b. No data available</td>
<td>b. No data available</td>
</tr>
<tr>
<td>Gadavist</td>
<td>a. Stojanov et al., 2016; Tedeschi et al., 2016; Bjornerud et al., in press</td>
<td>a. Radbruch et al., 2015a; Cao et al., 2016a; Radbruch et al., 2016; Schlemm et al., 2017; Kromrey et al., 2017; Bae et al., 2017; Radbruch et al., 2017b; Langner et al., 2017; Müller et al., 2017; Yoo et al., 2017</td>
</tr>
<tr>
<td></td>
<td>a. No data available</td>
<td>b. No data available</td>
</tr>
<tr>
<td>MultiHance</td>
<td>a. Weberling et al., 2015</td>
<td>a. Ramalho et al., 2015; Ramalho et al., 2016b</td>
</tr>
<tr>
<td></td>
<td>b. Schneider et al., 2017</td>
<td>b. Schneider et al., 2017</td>
</tr>
<tr>
<td>OptiMARK</td>
<td>No data available</td>
<td>No data available</td>
</tr>
</tbody>
</table>

MIDAC Meeting – September 8, 2017
Assessment of Potential Toxicity in Animals

• Data from animal experiments did not show histological or clinical signs of neurotoxicity deriving from brain Gd retention in adult and juvenile animals.¹
  • No histological changes ever observed in animals treated up to 50 mmol/kg (still a no-effect dose), corresponding to 83 standard doses of 0.1 mmol/kg, with assessments performed up to 50 weeks after dosing
  • Longitudinal neuro-behavioral assessments did not show any abnormality
  • As no toxic effects were observed (any cumulative dose, any Gd level in brain tissues), no threshold for toxic levels could be established

• Body retention: skin lesions observed following repeated doses of Omniscan or OptiMARK (but not of any other GBCAs).²
  • The observed skin changes were characterized by dermal fibrosis and infiltration of different cells, including mononuclear cells and CD34-positive cells

¹ Bracco Briefing Material, Section 3.1.2; ² Bracco Briefing Material, Section 3.2.1
No Evidence of Adverse Health Effects of Gd Retention in Humans

- No evidence of neurotoxicity from tissue-sample studies in human patients ¹
- No association between exposure to GBCAs and neurological adverse effects ²
  - No association between exposure to GBCAs and development of parkinsonism in patients >65 years of age (Welk et al., JAMA 2016; follow-up: approx. 4 years)
  - Results of a prospective cohort study (Mayo Clinical Study of Aging) in 4,261 patients, with 2,946 controls and 1,315 patients >70 yrs of age exposed to Omniscan (742 ≤4 doses, and 573 ≥5 doses; median follow-up: 5.6 years) and undergoing periodic monitoring of cognitive function and motoric skills
    - Omniscan exposure was not a predictor of excess cognitive decline or altered motor performance compared to controls
- No clear association between body Gd retention and sporadic non-NSF adverse events ³

¹ Bracco Briefing Material, Section 3.1.3.1; ² Bracco Briefing Material, Section 3.1.3.2; ³ FDA Briefing Material, Section 2: Pharmacovigilance
Risk Assessment
Gd Retention – Risk Assessment Beyond NSF

Retention of Gd Complexes in Human Patients With or Without Impairment of Renal Function

All GBCAs Determine Retention of Gd Complexes in Brain and Body Tissues (Possibly Higher with Certain Linear Agents)

Brain Tissues

- T1 Hyperintensity in Deep Brain Areas
- No Evidence of Association with Adverse Neurological Effects – Risk Still Unknown

Extracerebral (Body) Tissues

- No Clear Association between exposure to GBCAs and Reports of Non-NSF Adverse Events – Risk Still Unknown

MIDAC Meeting – September 8, 2017
Proposal For Risk Mitigation Measures
Labeling Enhancement and Education

- In order to minimize the risk of Gd retention, the prescribing information for each GBCA (including MultiHance and ProHance) should contain tailored, clear warnings regarding the potential for:
  - Gd retention in tissues also in patients with normal renal function, to a) make the health care professionals aware, and b) reduce exposure (ALARA principle)
  - Visible T1 hyperintensity in deep brain areas on unenhanced brain MR images, to increase awareness and avoid any potential, even if unlikely, effect of abnormal T1 shortening on image interpretation
  - Late-onset symptoms in patients with normal renal function (even if the association of these events and exposure to GBCAs is still unknown)
  - FDA-approved information to healthcare professionals (e.g., Dear Health Care Provider Letters) and educational programs validated by FDA
Conclusions

• The recent findings on long-term Gd retention following exposure to GBCAs are taken very seriously by Bracco

• Gd retention has been associated with all of the GBCAs available, regardless of their chemical structure
  • It is neither possible nor appropriate to draw a demarcation line between groups of agents only based on their chemical structure
  • It is important to look attentively at differences (or absence of differences) between individual GBCAs (not classes)

• Bracco fully supports FDA’s sensible position to adjust labeling, to inform health care providers and the public about Gd retention, and to encourage more research in this area
Thank you